https://biopharmchina.com/ 2026-09-11T14:43:13+00:00 https://biopharmchina.com/inno-medicine-secures-nearly-110m-to-advance-targeted-nanomedicines-for-atherosclerosis-and-glioma/ 2026-09-11T14:43:13+00:00 https://biopharmchina.com/chinas-personalized-mrna-cancer-vaccine-race-accelerates-after-moderna-and-mercks-phase-3-melanoma-success/ 2026-09-11T14:23:38+00:00 https://biopharmchina.com/hutchmed-licenses-kras-egfr-attc-hmpl-a830-to-gsk-in-deal-worth-up-to-1-295-billion/ 2026-09-11T14:23:10+00:00 https://biopharmchina.com/genocurys-in-vivo-car-t-jy231-shows-early-promise-in-refractory-neurologic-autoimmune-diseases/ 2026-09-11T14:22:43+00:00 https://biopharmchina.com/akesos-ivonescimab-outshines-pembrolizumab-on-overall-survival-in-phase-3-harmoni-2-trial/ 2026-09-11T14:22:32+00:00 https://biopharmchina.com/cttqs-her2-bispecific-adc-tqb2102-hits-phase-3-endpoints-in-her2-low-breast-cancer-setting-up-china-filing/ 2026-09-11T14:22:20+00:00 https://biopharmchina.com/unike-biopharma-raises-tens-of-millions-of-rmb-to-advance-long-acting-protein-and-peptide-drug-platform/ 2026-09-11T14:18:08+00:00 https://biopharmchina.com/1cbio-licenses-parp1-inhibitor-oc-3-to-lees-pharm-in-27-million-asia-deal/ 2026-09-11T13:54:04+00:00 https://biopharmchina.com/windward-bios-win378-delivers-positive-phase-2-asthma-data-as-twice-yearly-anti-tslp-antibody-moves-into-phase-3/ 2026-09-10T13:55:29+00:00 https://biopharmchina.com/iregenes-nouvsight001-cleared-for-retinitis-pigmentosa-trials-in-china-and-u-s/ 2026-09-10T13:33:41+00:00 https://biopharmchina.com/lumiere-therapeutics-raises-over-rmb-100-million-to-advance-epigenetic-editing-therapies/ 2026-09-09T14:46:26+00:00 https://biopharmchina.com/clover-biopharmas-rsv-hmpv-piv3-combination-vaccines-deliver-encouraging-phase-2-results-in-older-adults/ 2026-09-09T02:04:04+00:00 https://biopharmchina.com/bic-2026-8th-asia-biologics-innovation-conference/ 2026-09-08T19:25:18+00:00 https://biopharmchina.com/aipher-raises-rmb-100-million-angel-round-to-build-ai-native-drug-discovery-platform/ 2026-09-07T00:25:43+00:00 https://biopharmchina.com/china-nmpa-clears-five-novel-drugs-and-two-new-indications-in-september-approval-wave/ 2026-09-06T21:48:44+00:00 https://biopharmchina.com/simcere-zaiming-out-licenses-sim0660-a-tri-specific-t-cell-engager-to-roche-in-1-53-billion-global-deal/ 2026-09-06T20:35:36+00:00 https://biopharmchina.com/apichopes-ar882-beats-febuxostat-in-china-phase-3-gout-trial-meeting-primary-endpoint/ 2026-09-06T01:57:35+00:00 https://biopharmchina.com/ascletis-doses-first-participant-in-global-phase-iii-program-of-oral-glp-1-drug-asc30/ 2026-08-31T18:44:53+00:00 https://biopharmchina.com/brl-medicines-brl-101-meets-primary-endpoint-in-pivotal-trial-for-transfusion-dependent-%ce%b2-thalassemia/ 2026-08-31T18:35:30+00:00 https://biopharmchina.com/chinas-nmpa-conditionally-approves-velinotamig-for-heavily-pretreated-multiple-myeloma/ 2026-08-31T18:20:24+00:00 https://biopharmchina.com/allyrna-raises-over-rmb-100-million-to-advance-rna-epigenetics-based-cancer-drug-pipeline/ 2026-08-31T15:09:14+00:00 https://biopharmchina.com/convergen-closes-15-million-financing-to-advance-novel-protein-degradation-therapies-for-neurodegenerative-diseases/ 2026-08-31T14:56:38+00:00 https://biopharmchina.com/2026-h2-abbvie-china-partnering-day/ 2026-08-31T14:17:43+00:00 https://biopharmchina.com/leaderna-therapeutics-completes-series-a-financing-to-advance-small-nucleic-acid-drug-pipeline/ 2026-08-31T13:59:08+00:00 https://biopharmchina.com/simnova-raises-nearly-rmb-400-million-in-series-b-financing-to-advance-car-nk-and-in-vivo-car-t-platforms/ 2026-08-31T13:50:28+00:00 https://biopharmchina.com/2026-global-xdc-innovation-conference/ 2026-08-31T00:12:55+00:00 https://biopharmchina.com/sichuan-biokin-pharmaceutical/ 2026-08-30T16:16:56+00:00 https://biopharmchina.com/wp-content/uploads/2026/08/biokin_pipeline.jpg https://biopharmchina.com/kelun-biotech-biopharma/ 2026-08-30T16:14:15+00:00 https://biopharmchina.com/wp-content/uploads/2026/08/kelun-biotech_pipeline2026.jpg https://biopharmchina.com/chia-tai-tianqing-pharma-cttq/ 2026-08-30T16:13:10+00:00 https://biopharmchina.com/wp-content/uploads/2026/08/CTTQ_pipeline.jpg https://biopharmchina.com/kelun-biotechs-trop2-adc-sac-tmt-shows-durable-activity-across-genomically-altered-nsclc-in-a-phase-2-study/ 2026-08-30T15:44:52+00:00 https://biopharmchina.com/kelun-biotech-seeks-marketing-approval-on-sac-tmt-for-the-first-line-treatment-of-pd-l1-negative-tnbc/ 2026-08-30T15:44:17+00:00 https://biopharmchina.com/cstone-pharmaceuticals/ 2026-08-30T15:42:07+00:00 https://biopharmchina.com/wp-content/uploads/2026/08/CStonePharmaPipeline_AUG2026-1.jpg https://biopharmchina.com/innovents-once-weekly-oral-glp-1-ibi3042-gets-nmpa-ind-clearance-for-obesity/ 2026-08-30T01:43:42+00:00 https://biopharmchina.com/lanova-medicines-next-generation-nectin-4-adc-lm-364-wins-china-ind-clearance-for-advanced-solid-tumors/ 2026-08-30T01:32:53+00:00 https://biopharmchina.com/livzon-kanovas-lecankitug-gets-china-approval-after-beating-secukinumab-in-phase-iii-psoriasis-trial/ 2026-08-28T18:57:28+00:00 https://biopharmchina.com/hutchmeds-fanregratinib-wins-china-nmpa-approval-for-fgfr2-intrahepatic-cholangiocarcinoma-icc/ 2026-08-28T18:37:19+00:00 https://biopharmchina.com/biokins-iza-bren-hits-phase-3-pfs-endpoint-in-egfr-mutant-nsclc-marking-4th-positive-phase-3-trial/ 2026-08-28T16:02:39+00:00 https://biopharmchina.com/hutchmeds-savolitinib-tagrisso-combo-delivers-positive-phase-3-results-in-met-driven-egfr-mutated-nsclc/ 2026-08-28T16:02:14+00:00 https://biopharmchina.com/keymed-biosciences-completed-phase-ii-trial-of-cm512-a-tslp-x-il-13-bispecific-antibody-for-chronic-sinusitis/ 2026-08-28T16:01:39+00:00 https://biopharmchina.com/hansohs-hs-20093-met-its-phase-iii-goals-strengthening-its-status-as-a-top-b7-h3-adc-contender/ 2026-08-28T16:01:00+00:00 https://biopharmchina.com/genfleet-launches-worlds-first-phase-iii-study-of-an-oral-kras-g12d-inhibitor-for-the-treatment-of-nsclc/ 2026-08-28T16:00:05+00:00 https://biopharmchina.com/wp-content/uploads/2026/08/Image_20260811111237.jpg https://biopharmchina.com/akesos-ivonescimab-beats-durvalumab-standard-in-phase-3-biliary-tract-cancer-trial/ 2026-08-28T15:58:00+00:00 https://biopharmchina.com/biokins-iza-bren-hits-phase-3-pfs-endpoint-in-hr-her2%e2%88%92-breast-cancer-marking-5th-phase-3-success/ 2026-08-28T15:57:28+00:00 https://biopharmchina.com/cspcs-egfr-adc-sys6010-beats-chemotherapy-in-phase-iii-nsclc-trial-setting-stage-for-potential-regulatory-filing/ 2026-08-28T15:56:58+00:00 https://biopharmchina.com/haiscos-class-1-small-molecule-pnh-drug-has-been-approved-for-marketing-in-china/ 2026-08-28T15:49:47+00:00 https://biopharmchina.com/xellsmarts-universal-cell-therapy-drug-for-parkinsons-disease-receives-fast-track-designation-from-the-us-fda/ 2026-08-28T15:48:56+00:00 https://biopharmchina.com/leads-biolabs-opamtistomig-nda-accepted-in-china-setting-up-potential-world-first-4-1bb-therapy/ 2026-08-28T15:43:43+00:00 https://biopharmchina.com/aiming-at-a-undruggble-target-pyrotechs-class-1-small-molecule-candidate-gets-approved-for-sepsis-clinical-trials/ 2026-08-28T15:43:10+00:00 https://biopharmchina.com/hengrui-advances-shr-8203-into-phase-1-2-study-in-advanced-solid-tumors-with-filing-hinting-at-potential-pd-1-vegf-ctla-4-trispecific/ 2026-08-28T15:42:34+00:00 https://biopharmchina.com/tyk-medicines-wins-china-approval-for-asandeutertinib-in-egfr-mutant-nsclc-with-brain-metastases/ 2026-08-28T15:36:59+00:00 https://biopharmchina.com/ausperbio-raises-120-million-series-c-to-advance-ahb-137-toward-hepatitis-b-functional-cure-and-commercialization/ 2026-08-28T14:57:56+00:00 https://biopharmchina.com/dualitybio-partners-with-genentech-in-1b-plus-next-generation-adc-collaboration-built-around-novel-payload-platform/ 2026-08-28T14:14:53+00:00 https://biopharmchina.com/haisco-pharmaceutical-group/ 2026-08-27T23:13:24+00:00 https://biopharmchina.com/wp-content/uploads/2026/08/haisco_pipeline.jpg https://biopharmchina.com/akeso-inc/ 2026-08-27T23:06:59+00:00 https://biopharmchina.com/wp-content/uploads/2026/08/Aesko_pipeline-1.jpg https://biopharmchina.com/henlius-expands-sandoz-partnership-in-up-to-322-million-biosimilars-deal/ 2026-08-27T23:00:09+00:00 https://biopharmchina.com/haisco-strikes-1-5-billion-newco-deal-with-sentivera-for-type-2-inflammation-asset/ 2026-08-27T16:17:36+00:00 https://biopharmchina.com/bio-thera-and-avalon-pharma-sign-mena-deal-for-bat2406-proposed-dupixent-biosimilar/ 2026-08-27T15:40:17+00:00 https://biopharmchina.com/dajo-bio-raises-tens-of-millions-of-rmb-in-seed-financing-to-advance-next-generation-tcr-protein-therapies/ 2026-08-27T15:33:58+00:00 https://biopharmchina.com/navi-therapeutics-raises-series-a-to-advance-ai-driven-next-generation-adc-platform/ 2026-08-27T15:24:12+00:00 https://biopharmchina.com/bioshanghai-week-2026/ 2026-08-27T14:33:02+00:00 https://biopharmchina.com/china-medicine-connect-expo-2026/ 2026-08-27T14:30:30+00:00 https://biopharmchina.com/cbi-2026-xdc-drug-development-conference/ 2026-08-27T14:30:13+00:00 https://biopharmchina.com/cbi-2026-antibody-drug-development-conference/ 2026-08-27T14:29:57+00:00 https://biopharmchina.com/clinical-trial-supply-china-2026/ 2026-08-27T14:29:38+00:00 https://biopharmchina.com/cphi-pmec-shenzhen-2026/ 2026-08-27T14:29:22+00:00 https://biopharmchina.com/merck-and-inventisbio-signed-a-collaboration-agreement-to-advance-clinical-development-of-small-molecule-cancer-drugs/ 2026-08-19T02:41:13+00:00 https://biopharmchina.com/cspc-and-astrazeneca-joint-venture-a-new-logic-for-mncs-to-build-factories-in-china/ 2026-08-19T02:38:47+00:00 https://biopharmchina.com/beigene-and-revolution-medicines-enter-strategic-collaboration/ 2026-08-19T02:38:03+00:00 https://biopharmchina.com/wp-content/uploads/2025/05/rvmd.png https://biopharmchina.com/hopstem-completes-nearly-200-million-yuan-series-c-financing-to-accelerate-its-core-ipsc-programs/ 2026-08-19T02:34:55+00:00 https://biopharmchina.com/magicrna-raises-hundreds-of-millions-of-yuan-in-series-b-financing-to-advance-worlds-first-in-vivo-car-t-therapy/ 2026-08-19T02:33:25+00:00 https://biopharmchina.com/iregene-secures-another-260-million-yuan-in-series-c-financing-to-accelerate-pipeline-development/ 2026-08-19T02:31:12+00:00 https://biopharmchina.com/xgene-secured-rmb-250-million-in-series-d-financing-to-develop-novel-non-opioid-analgesic-drugs/ 2026-08-17T18:22:55+00:00 https://biopharmchina.com/alphamab-oncology-and-pathos-reach-international-licensing-agreement-for-trop2-her3-bispecific-adc/ 2026-08-17T16:48:41+00:00